AtriCure (ATRC) Competitors $34.73 -0.08 (-0.23%) Closing price 04:00 PM EasternExtended Trading$34.75 +0.02 (+0.06%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATRC vs. TFX, ITGR, ATEC, IART, OFIX, ANGO, SRDX, ARAY, RMTI, and ABTShould you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), Integra LifeSciences (IART), Orthofix Medical (OFIX), AngioDynamics (ANGO), Surmodics (SRDX), Accuray (ARAY), Rockwell Medical (RMTI), and Abbott Laboratories (ABT). These companies are all part of the "health care equipment" industry. AtriCure vs. Its Competitors Teleflex Integer Alphatec Integra LifeSciences Orthofix Medical AngioDynamics Surmodics Accuray Rockwell Medical Abbott Laboratories Teleflex (NYSE:TFX) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability. Do insiders & institutionals hold more shares of TFX or ATRC? 95.6% of Teleflex shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 1.4% of Teleflex shares are held by company insiders. Comparatively, 3.5% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is TFX or ATRC more profitable? Teleflex has a net margin of 6.31% compared to AtriCure's net margin of -7.27%. Teleflex's return on equity of 15.08% beat AtriCure's return on equity.Company Net Margins Return on Equity Return on Assets Teleflex6.31% 15.08% 8.85% AtriCure -7.27%-4.20%-3.19% Which has preferable valuation and earnings, TFX or ATRC? Teleflex has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeleflex$3.04B1.85$69.68M$4.2530.04AtriCure$499.95M3.45-$44.70M-$0.77-45.10 Do analysts prefer TFX or ATRC? Teleflex currently has a consensus price target of $141.57, indicating a potential upside of 10.90%. AtriCure has a consensus price target of $50.89, indicating a potential upside of 46.53%. Given AtriCure's stronger consensus rating and higher possible upside, analysts plainly believe AtriCure is more favorable than Teleflex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teleflex 2 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.92AtriCure 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility and risk, TFX or ATRC? Teleflex has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Does the media prefer TFX or ATRC? In the previous week, Teleflex had 4 more articles in the media than AtriCure. MarketBeat recorded 5 mentions for Teleflex and 1 mentions for AtriCure. Teleflex's average media sentiment score of 0.20 beat AtriCure's score of 0.00 indicating that Teleflex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teleflex 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AtriCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTeleflex beats AtriCure on 9 of the 16 factors compared between the two stocks. Get AtriCure News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRC vs. The Competition Export to ExcelMetricAtriCureMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.73B$10.59B$6.15B$10.62BDividend YieldN/A1.84%5.64%4.69%P/E Ratio-45.1022.2285.6627.13Price / Sales3.4535.30527.36205.87Price / CashN/A25.6126.3031.10Price / Book3.673.4812.926.67Net Income-$44.70M$210.63M$3.30B$276.23M7 Day Performance-0.40%2.52%4.80%3.31%1 Month Performance-1.84%2.31%8.11%10.76%1 Year Performance25.70%-6.64%75.85%33.58% AtriCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRCAtriCure2.4254 of 5 stars$34.73-0.2%$50.89+46.5%+26.0%$1.73B$499.95M-45.101,300Positive NewsTFXTeleflex4.6103 of 5 stars$120.65+0.6%$141.57+17.3%-45.2%$5.30B$3.04B28.3914,100ITGRInteger4.0982 of 5 stars$101.06-0.4%$140.25+38.8%-18.5%$3.56B$1.72B44.5211,000ATECAlphatec4.4952 of 5 stars$14.75-1.8%$18.50+25.4%+154.3%$2.22B$682.24M-13.05700Positive NewsInsider TradeIARTIntegra LifeSciences4.0125 of 5 stars$13.63+3.3%$18.43+35.2%-12.9%$1.03B$1.61B-2.094,396Positive NewsOFIXOrthofix Medical2.9318 of 5 stars$14.36+0.5%$21.75+51.5%-4.4%$564.37M$799.49M-4.531,616ANGOAngioDynamics4.07 of 5 stars$10.74+0.6%$19.00+76.9%+90.8%$433.97M$292.50M-12.94760Earnings ReportAnalyst ForecastSRDXSurmodics4.5449 of 5 stars$29.91-0.1%$43.00+43.8%-24.2%$428.07M$126.08M-24.32450Positive NewsARAYAccuray4.4936 of 5 stars$1.63-2.4%$5.00+206.7%-11.5%$188.17M$458.51M-81.501,040Gap UpRMTIRockwell Medical3.3037 of 5 stars$1.27flat$4.00+215.0%-66.5%$43.73M$87.97M-21.17300Positive NewsShort Interest ↑ABTAbbott Laboratories4.9577 of 5 stars$133.01-0.4%$145.22+9.2%+19.4%$232.44B$43.11B16.67114,000Positive News Related Companies and Tools Related Companies TFX Competitors ITGR Competitors ATEC Competitors IART Competitors OFIX Competitors ANGO Competitors SRDX Competitors ARAY Competitors RMTI Competitors ABT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRC) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWarren Buffett’s #1 AI Stock is Not Even on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
